What is the core technology behind Nemus Bioscience?

Nemus focuses on proprietary cannabinoid prodrugs and analogues. According to slide 9, their technology is designed to improve drug delivery by enhancing bioavailability and ensuring predictable pharmacokinetics. They achieve this by utilizing ocular, transmucosal (suppositories and patches), and transmembranous (nasal and transdermal) delivery routes to bypass the liver's first-pass metabolism.

Which medical conditions is Nemus targeting?

As shown on slide 5, the portfolio includes treatments for Glaucoma (NB1111), Chemotherapy-Induced Nausea and Vomiting (NB1222), Chemotherapy-Induced Peripheral Neuropathy (NB2111), various ocular diseases like dry eye and macular degeneration (NB2222), and anti-infective applications for MRSA and viral species (NB3111).

What is the current developmental stage of their products?

Based on the portfolio summary on slide 5, the lead candidates NB1111 (Glaucoma) and NB1222 (CINV) are in the Pre-Clinical stage. The remaining three programs, including the CBD analogues and the MRSA anti-infective platform, are in the earlier Research phase.

How does Nemus plan to navigate the FDA approval process?

For their CINV candidate (NB1222), slide 21 notes they intend to file a New Drug Application (NDA) via the 505(b)(2) regulatory pathway. This is an expedited route often used for new formulations of previously approved drugs, which can significantly reduce the time and cost of clinical trials.

Who leads the company and what is their background?

Slide 37 highlights Executive Chairman and Co-founder Cosmas N. Lykos. He is a Duke University School of Law graduate with an extensive background in legal and corporate compliance, having served as an officer for public companies like Oakley, Inc. and RemedyTemp, Inc. before co-founding Nemus in 2012.

Nemus Bioscience Pitch Deck (2017): 39-Slide Breakdown

See all 39 slides of the Nemus Bioscience pitch deck — a 2017 deck — with a slide-by-slide teardown of what the deck does well and where it falls short.

Nemus Bioscience’s February 2017 deck is a technical, science-heavy presentation typical of a publicly traded biotech firm. The company focuses on bio-engineered cannabinoid prodrugs and analogues to address indications like glaucoma, chemotherapy-induced nausea (CINV), and MRSA. By targeting delivery methods that bypass first-pass liver metabolism, Nemus aims to solve the bioavailability issues common in traditional cannabinoid therapies. The deck relies heavily on market size projections—totaling over $68 billion across five candidates—and pre-clinical data, such as rabbit eye studies. Whil…

Key takeaways

The company targets five distinct drug candidates with a combined projected global market size exceeding $68 billion (Slide 5).
Nemus utilizes a prodrug strategy to enhance bioavailability and provide predictable pharmacokinetics by avoiding first-pass liver metabolism (Slide 9).
Glaucoma is the lead indication for NB1111, targeting an $8 billion global market where 50% of patients are currently on two or more prescriptions (Slide 13).
Pre-clinical data for NB1111 shows drug localization in ocular organs with no THC detected in plasma after five days of dosing (Slide 17).
The NB1222 candidate for CINV seeks an expedited 505(b)(2) regulatory pathway to compete in a $2 billion market (Slide 21).
Nemus is expanding into anti-infectives, specifically targeting Methicillin-resistant Staph aureus (MRSA) using a cannabinoid platform (Slide 33).
The management team is led by Cosmas N. Lykos, a co-founder with significant experience in public company legal and compliance roles (Slide 37).
The deck lacks a specific 'Ask' slide or detailed financial use-of-funds breakdown within the provided 10-slide sample.

Introduction and Market Positioning

Slide 1: Title Slide

The presentation opens with the Nemus Bioscience logo and their OTCQB ticker symbol: NMUS. The date is clearly marked as February 2017. The background image features laboratory test tubes, signaling a focus on clinical research and biotechnology. There is no tagline or mission statement on the cover slide, keeping the focus entirely on the corporate identity and its public trading status.

Slide 5: Nemus Cannabinoid Development Portfolio

This slide provides a comprehensive overview of the company's pipeline. It lists five distinct drug candidates and their target indications. NB1111 (Prodrug THC) targets Glaucoma with a projected global market size of $8 billion and is in the Pre-Clinical stage. NB1222 (Prodrug THC) targets Chemotherapy-Induced Nausea and Vomiting (CINV) with a $2 billion market, also in Pre-Clinical. The remaining three candidates— NB2111 , NB2222 , and NB3111 —target pain, ocular diseases, and MRSA respectively, with market sizes ranging from $6 billion to over $30 billion. All three are currently in the Research phase. The slide cites sources like IMS Midas and Transparency Market Research for these figures.

Technical Strategy and Delivery Mechanisms

Slide 9: Innovative Cannabinoid Formulations

Nemus outlines its technical differentiator here: improved drug delivery. The slide states that all licensed delivery options optimize their prodrug technology by enhancing bioavailability and avoiding first-pass liver metabolism . They list three specific delivery routes: Ocular delivery for glaucoma, Transmucosal delivery (suppositories and buccal patches) for CINV and CIPN, and Transmembranous delivery (nasal/transdermal) for anti-infectives like MRSA. This slide is critical as it explains the 'how' behind their clinical strategy.

Slide 13: The Glaucoma Market

Focusing on their lead candidate, this slide details the Glaucoma opportunity. It notes that the global market is $8 billion, with a $2.3 billion US market representing 32 million prescriptions. Key strategic points include a well-defined regulatory pathway and the potential for "urgent medical need" or "breakthrough therapy" FDA designations. Notably, the slide points out that over 50% of patients are "non-responders" who require two or more prescriptions, representing a significant gap in current care.

Slide 17: Ocular Tissue Concentration Data

This is a highly technical data slide showing the results of a PK-PD (pharmacokinetic-pharmacodynamic) comparison in rabbit eyes. The chart tracks drug concentration in various parts of the eye (aqueous humor, iris/ciliary body, etc.) over 120 minutes. The key takeaways listed are that the drug localizes to the ocular organs responsible for IOP (intraocular pressure) regulation and, crucially, no THC was detected in the plasma of the study animals even after five days of dosing. This supports their claim of localized delivery without systemic side effects.

Secondary Indications and Market Expansion

Slide 21: NB1222 for CINV

This slide addresses the Chemotherapy-Induced Nausea and Vomiting market. It cites 15 million global cancer cases, with 70-80% of chemotherapy recipients experiencing CINV. The slide mentions Dronabinol (a synthetic THC) as a competitor with over $110 million in annual sales. Nemus plans to develop a suppository version of their prodrug, NB1222, and intends to use the 505(b)(2) expedited regulatory pathway for its NDA filing.

Slide 25: CIPN Section Header

A simple transition slide for Chemotherapy-Induced Peripheral Neuropathy (CIPN), identifying NB2111 as an analogue of CBD. This indicates a shift from THC-based prodrugs to CBD-based analogues for pain management.

Slide 31: MRSA as a Global Concern

This slide uses a collage of news headlines from The Economist and Daily Herald to establish the severity of the MRSA (superbug) crisis. It frames the problem as a "global urgent health concern" and a "fatal menace," moving the deck's narrative from chronic disease management to acute infectious disease threats.

Slide 33: Anti-Infective Platform for MRSA

Nemus explains their approach to MRSA, stating they have successfully screened a library of cannabinoids for bactericidal activity. They have identified "cannabinoid cocktails" with synergistic activity against multiple MRSA strains. The slide notes their intention to broaden their IP estate with synthetic molecules and mentions a goal to partner the platform in the H1 2017 timeframe to accelerate development.

Leadership and Governance

Slide 37: Management - Cosmas N. Lykos, Esq.

The final slide in the provided set profiles the Executive Chairman and Co-founder. Lykos's background is heavily weighted toward legal, compliance, and corporate governance. His experience includes roles as General Counsel and Chief Compliance Officer at public companies like Oakley, Inc. and RemedyTemp, Inc. The bio emphasizes his experience in negotiating licensing deals and managing foreign subsidiaries, which aligns with the company's strategy of licensing technology and seeking developmental partners.

What Works in This Deck

The Nemus deck excels at market quantification . By breaking down the specific dollar value and prescription volume for each indication (Slides 5, 13, 21), they provide a clear picture of the upside. The inclusion of pre-clinical data (Slide 17) is also a strength, as it provides empirical evidence for their claims regarding localized delivery and the absence of systemic THC. Furthermore, the regulatory strategy is well-articulated; mentioning the 505(b)(2) pathway (Slide 21) shows that the management team has a pragmatic plan for reaching the market faster than a standard drug development cycle might allow.

What Is Missing

The most glaring omission in this 10-slide sample is a financial slide . There is no mention of current cash runway, burn rate, or the specific amount of capital being raised. While the company is public (OTCQB), an investor deck usually includes a use-of-funds breakdown. Additionally, while the management slide for the Executive Chairman is detailed, there are no slides for the scientific team or Chief Medical Officer in this selection. In a biotech play, the scientific pedigree is often as important as the legal/compliance background. Finally, there is a lack of competitive landscape analysis beyond a brief mention of Dronabinol; a more robust comparison against existing glaucoma or MRSA treatments would strengthen the case.

What a Founder Should Copy

Founders in the life sciences space should emulate the Pipeline Table on Slide 5. It is a standard but highly effective way to show breadth and progress simultaneously. The use of third-party validation for market sizes (citing IMS and Pew Trust) is also a best practice that builds credibility. Another strong element is the visual Abbreviation Key on Slide 17; when presenting complex data, providing a legend on the same slide helps keep the audience engaged without forcing them to flip back to previous pages. Lastly, the clear distinction between delivery mechanisms (Slide 9) helps non-technical investors understand the company's unique value proposition in a crowded field.

Frequently asked questions

What is the core technology behind Nemus Bioscience?: Nemus focuses on proprietary cannabinoid prodrugs and analogues. According to slide 9, their technology is designed to improve drug delivery by enhancing bioavailability and ensuring predictable pharmacokinetics. They achieve this by utilizing ocular, transmucosal (suppositories and patches), and transmembranous (nasal and transdermal) delivery routes to bypass the liver's first-pass metabolism.
Which medical conditions is Nemus targeting?: As shown on slide 5, the portfolio includes treatments for Glaucoma (NB1111), Chemotherapy-Induced Nausea and Vomiting (NB1222), Chemotherapy-Induced Peripheral Neuropathy (NB2111), various ocular diseases like dry eye and macular degeneration (NB2222), and anti-infective applications for MRSA and viral species (NB3111).
What is the current developmental stage of their products?: Based on the portfolio summary on slide 5, the lead candidates NB1111 (Glaucoma) and NB1222 (CINV) are in the Pre-Clinical stage. The remaining three programs, including the CBD analogues and the MRSA anti-infective platform, are in the earlier Research phase.
How does Nemus plan to navigate the FDA approval process?: For their CINV candidate (NB1222), slide 21 notes they intend to file a New Drug Application (NDA) via the 505(b)(2) regulatory pathway. This is an expedited route often used for new formulations of previously approved drugs, which can significantly reduce the time and cost of clinical trials.
Who leads the company and what is their background?: Slide 37 highlights Executive Chairman and Co-founder Cosmas N. Lykos. He is a Duke University School of Law graduate with an extensive background in legal and corporate compliance, having served as an officer for public companies like Oakley, Inc. and RemedyTemp, Inc. before co-founding Nemus in 2012.

Cover slide of the Nemus Bioscience pitch deck — Public (OTCQB) 2017 — Nemus Bioscience pitch deck, slide 1 (2017)

Nemus Bioscience pitch deck: the facts

Company: Nemus Bioscience
Year: 2017
Stage: Public (OTCQB)
Slides: 39
Sector: Biotechnology / Pharmaceuticals
Deck type: Investor Presentation
Outcome: Active (Later rebranded to Emerald Bioscience, then Skye Bioscience)
Headquarters: Costa Mesa, California, USA

Nemus Bioscience pitch deck PDF

The full Nemus Bioscience deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Nemus Bioscience pitch deck was used for

This is a February 2017 investor presentation for Nemus Bioscience, then an OTCQB-listed public biotech focused on cannabinoid therapeutics. The deck frames the company’s raise around advancing proprietary cannabinoid drug programs, especially ocular, transmucosal, and other delivery approaches designed to improve bioavailability and avoid first-pass metabolism. The presentation is also positioned against a near-term financing backdrop: the company had just closed a $1.2 million preferred stock financing in January 2017 and later announced a much larger $20 million Series E financing in May 2017.

Business model: Biopharmaceutical company developing and commercializing cannabinoid-based therapeutics through its partnership with the University of Mississippi.

Round: Series E preferred stock financing
Raised: $20,000,000
Lead investor: Schneider Finance LLC
Investors: Schneider Finance LLC (affiliate of Schneider Brothers Ltd.)
Founded: 2012
Founders: Cosmas N. Lykos
Headquarters: Costa Mesa, California (later SEC filings also reference Long Beach, California)
Industry: Biotechnology / Pharmaceuticals

Year: 2017; announced May 4, 2017

Total funding: At least $20 million in Series E preferred stock financing announced in May 2017; additional earlier financings are referenced in company filings and press releases, including a $1.2 million preferred stock financing closed in January 2017.

Use of funds as presented: To fund research and development activities of product candidates and for general corporate and working capital purposes.

What happened after the Nemus Bioscience deck

The deck itself is verified as a February 2017 Nemus investor presentation, and surrounding company announcements confirm active fundraising in 2017. The exact raise tied to this specific deck is not explicitly stated in the captured OCR, but the company announced a $1.2 million financing in January 2017 and a much larger $20 million Series E financing in May 2017.

January 2017: Nemus announced a $1.2 million preferred stock financing closed.
February 2017: this investor presentation was published on Slideshare.
May 2017: Nemus announced a $20 million Series E preferred stock financing.
2017: the company continued to describe development work on NB1111, NB1222, NB2111, and related delivery platforms.

What the Nemus Bioscience deck got right

Clear technical angle. The deck’s core thesis is specific and differentiated: cannabinoid-based therapeutics are paired with novel delivery methods intended to improve bioavailability and pharmacokinetics.
Strong IP and sourcing narrative. Nemus positions the University of Mississippi relationship as a major moat, including exclusive, perpetual, worldwide rights in the relevant fields.
Large addressable-market framing. The presentation links the platform to multiple large, recognizable therapeutic markets, including glaucoma, CINV, CIPN, retinal disease, and anti-infectives.
Some quantitative proof. The deck includes a concrete efficacy claim for glaucoma, citing a 45% decline in IOP, which gives the story at least one visible data point.
Visible execution cadence. The company shows progress through milestones such as in-licensing, manufacturing agreements, and collaboration arrangements, suggesting an active development program.

What could have been stronger

Use of proceeds is not explicit in the captured slides. The OCR excerpt does not show a clear use-of-proceeds slide, so the specific capital allocation being asked from investors is not visible from the provided text.
Clinical claims lack visible methodological detail. Several core efficacy claims are presented without visible trial design, sample size, comparator, or statistical context in the excerpt, including the cited 45% IOP decline in glaucoma.
Key partnership dependence is not fully specified. The deck relies heavily on partnership/IP claims with the University of Mississippi, but the excerpt does not show deal terms, field restrictions, termination rights, or dependence on any single collaborator.
Broad indication spread may dilute focus. The product story spans multiple indications and delivery routes at once, which can make the near-term development plan hard to evaluate from the excerpt alone.

How an investor would read this deck

What draws attention

The company’s thesis is built on cannabinoid prodrugs and analogues designed to improve bioavailability and avoid first-pass metabolism, which is the central technical bet of the deck.
The University of Mississippi relationship is presented as a major competitive moat, with exclusive, perpetual, worldwide rights in the relevant fields.
The deck ties platform value to multiple large markets: glaucoma and retinal disease, CINV, CIPN, and anti-infectives.
The presentation includes a specific glaucoma data point, stating a 45% decline in IOP, which is the strongest visible evidence claim in the excerpt.

Risks that stand out

Heavy dependence on cannabinoid IP and a single university relationship could create concentration risk.
The deck presents multiple indications and delivery modalities, which may indicate strategic breadth without clear prioritization.
Several efficacy statements are high-level and not supported by visible clinical rigor in the excerpt.
As a public OTCQB issuer, financing risk and dilution risk were likely material in 2017.

Questions this deck invites

What was the study design behind the 45% IOP decline claim, and was it replicated in a controlled setting?
What exactly were the terms, scope, and duration of Nemus’s exclusivity with the University of Mississippi, and what rights did UM retain?
Which programs were truly closest to human development in February 2017, and what milestones were funded by the round?
How much of the platform depended on successful manufacturing of proprietary APIs by AMRI and related third parties?
What was the company’s cash runway at the time of the deck, given the January 2017 financing and the later May 2017 Series E announcement?

What founders can take from the Nemus Bioscience deck

If the scientific moat is the story, the deck needs enough detail to make the moat legible: mechanism, IP scope, and why the delivery route matters.
A single quantitative result, like the stated 45% IOP reduction, can anchor the narrative if the deck also shows enough context to judge credibility.
When a company is building a platform across several indications, investors need a crisp sequencing plan or the story can feel overextended.
University-licensed life science companies should show the exact nature of the license and exclusivity, because that is often the real asset.
Public biotech decks that sit near financing announcements should make it easy to connect the raise to the next value-inflection milestones.

Nemus Bioscience pitch deck: common questions

What did Nemus Bioscience do in this deck?

Nemus Bioscience was a public OTCQB biotech developing cannabinoid-based therapeutics through a partnership with the University of Mississippi, with headquarters in Costa Mesa, California at the time of this deck.

What was this deck being used for?

The deck is dated February 2017 and appears to be a fundraising investor presentation, but the OCR excerpt does not explicitly state the exact use of proceeds on-slide. Company filings and the surrounding financing announcements show the company was raising to fund R&D and working capital.

What intellectual property did Nemus claim?

The presentation states Nemus had exclusive, perpetual, worldwide exclusivity for compounds and targets it was working on with the University of Mississippi in key delivery fields, and that patents had issued in the U.S., Japan, Australia, and the EU for its proprietary THC prodrug, with additional applications pending in Canada and Hong Kong.

Which drug programs were highlighted?

Yes. The deck highlights NB1111 for glaucoma, NB1222 for CINV, NB2111 as a CBD-like candidate, and additional delivery strategies for anti-infectives, including anti-MRSA applications.

Sources

Funding and outcome facts on this page were researched on 2026-08-22 from the pages below.

Nemus Bioscience pitch deck slides

Nemus Bioscience pitch deck slide 1 of 39 — Nemus Bioscience pitch deck — slide 1 of 39

Nemus Bioscience pitch deck slide 2 of 39 — Nemus Bioscience pitch deck — slide 2 of 39

Nemus Bioscience pitch deck slide 3 of 39 — Nemus Bioscience pitch deck — slide 3 of 39

Nemus Bioscience pitch deck slide 4 of 39 — Nemus Bioscience pitch deck — slide 4 of 39

Nemus Bioscience pitch deck slide 5 of 39 — Nemus Bioscience pitch deck — slide 5 of 39

Nemus Bioscience pitch deck slide 6 of 39 — Nemus Bioscience pitch deck — slide 6 of 39

What each slide of the Nemus Bioscience pitch deck says

Slide 2

Forward Looking Statement — —" This presentation contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All of the statements in this presentation, whether written or oral, that refer to expected or anticipated future actions and results of NEMUS Bioscience, Inc. (NEMUS) are forward-looking statements. These forward-looking statements reflect the beliefs and expectations of the management of NEMUS as of the date of this presentation. NEMUS cannot give any assurance that such forwardlooking statements will prove to be correct. The reader is cautioned not to place undue reliance on these forwardlooking…

Slide 3

Company Overview r——meme————-—_ _€_€@_€_—— NEMUS Bioscience is a publicly traded, life-science biotech company, focused on developing regulatory-approved, cannabinoid-based therapies, for a spectrum of diseases, especially those of unmet medical need 0TCQB NMUS > JTS ) $0.46/share | > SN / 3 > \ Price (2/7/17) 52-week high/low: $1.80/$0.30 » £0 xX Market Cap (2/7/17) $20.7 M on fully converted basis : J« . ! NS Shares Outstanding 45 M if 100% fully converted 1 () % Ownership by Directors & Officers he shares & A FA XR : options fd 4 Warrants Outstanding 11.5 M (Avg. Strike @ $0.40) / Founded 2012 B £0, i Costa Mesa, California 4 7, 74 ASRIONLIREIANons & Oxford, Mississippi ’ . 3

Slide 4

NEMUS Value Proposition: Disrupting the cannabinoid therapeutic space gnemus 10S5CIENCE * NEMUS is developing cannabinoid molecules for the treatment and/or management of acute and chronic diseases, especially those of unmet medical need * NEMUS is the sole development and commercialization partner of the University of Mississippi, drawing on 48 years of intellectual capital in cannabinoid chemistry and physiology from the only entity with a Federal license to directly study cannabinoids * NEMUS is advancing therapeutics for medical applications in, to our knowledge, global multi-billion dollar markets including: v' The only cannabinoid company advancing therapeutic platforms for multiple i…

Slide 5

Nemus Cannabinoid Development Portfolio " re ————————————————————————————————————————— Drug Candidate Target Indications Projected Developmental Global stage Market Size NB1111 (Prodrug THC) Glaucoma $gB! Pre-Clinical NB1222 (Prodrug THC) Chemotherapy-Induced $2B2 Pre-Clinical Nausea and Vomiting (CINV) NB2111 (Analogue CBD) Chemotherapy-Induced = 3 Research Peripheral Neuropathy (CIPN); $308 pain syndromes NB2222 (Analogue CBD) Ocular Targets: uveitis, dry eye >$22 8B Research syndrome, macular degeneration, diabetic retinopathy Cannabinoid Platform Methicillin-resistant Staph >$6B 4 Research NB3111 aureus (MRSA); gram-positive bacteria; viral species 1. IMS Midas data; 2015 2. Transparenc…

Slide 6

NEMUS Recent Milestones Recent Milestones * December 2015: NEMUS in-licenses CBD derivatives from UM and initiates research into chemotherapy induced peripheral neuropathy (CIPN) * January 2016: NEMUS announces validation of NB1111 data in glaucoma with 45% decline in IOP as NEMUS becomes leading cannabinoid drug developer in ophthalmology * January 2016: NEMUS announces initiation of development program for chemotherapy-induced nausea and vomiting (CINV) * February 2016: NEMUS signs agreement with AMRI to manufacture proprietary API for glaucoma (NB1111) and CINV (NB1222) programs * June 2016: NEMUS announces successful identification of CBD-like candidate molecule (NB2111) with significan…

Slide 7

June, 2016: Nemus collaborates to "disrupt" the cannabinoid market Nemus is dedicated to "disrupting" the cannabinoid space by introducing prodrug and analogue versions of cannabinoids that are designed to improve efficacy and safety versus naturally derived counterparts Nemus signed a definitive license agreement with Teewinot Life Science Corp. and AMRI to manufacture biosynthetically produced cannabinoid molecules based on Nemus' proprietary prodrug/analogue technology Nemus believes biosynthetically produced cannabinoids offer significant cost-efficient manufacturing and enhanced production scheduling not associated with plant-derived or chemically synthesized production The collaborati…

Slide 8

NEMUS Proprietary Cannabinoid Drug Programs Hold Competitive Advantages "NEMUS - Wesra Orally administered cannabinoids (both pill and spray delivery mechanisms) hold a variety of disadvantages for patients: * Poor bioavailability vs other routes of administration * Irregular pharmacokinetics secondary to Gl absorption * Susceptible to significant first-pass metabolism by the liver ¢ Regulatory findings of oral and sublingual spray delivery: NEMUS prodrug technology designed to capitalize on the — "Due to extensive first-pass metabolism and high lipid use of proprietary solubility, a fraction of the drug reaches the circulation"! formulations that could — "The pharmacologic effects of Marin…

Slide 9

Innovative Cannabinoid Formulations Designed for Improved Drug Delivery #NEMUS EEEEEEEEEE All NEMUS licensed delivery options optimize our prodrug cannabinoid technology by enhancing bioavailability by avoiding first-pass liver metabolism and offering more predictable pharmacokinetics * Ocular delivery: Glaucoma & retinal diseases * Transmucosal delivery: CINV & CIPN (suppository & buccal patch) * Transmembranous delivery: Anti-infectives (Anti-MRSA) (nasal/transdermal/ transmembraneous delivery)

Slide 10

Exclusive strategic relationship with the University of Mississippi provides access to a diverse cannabinoid patent estate TN L o\ ¥ National Center for '7 Mm Natural Products Research = * The University of Mississippi (UM) is the only entity in the US authorized by NIDA and the DEA to cultivate cannabis on behalf of the federal government for more than 49 years * NEMUS has exclusive, perpetual, worldwide exclusivity for all compounds and targets we are working on with UM for key fields of delivery * Patents have been issued for the proprietary prodrug of THC in the USA (2014), Japan (2015), Australia (2016); EU (2017); patents pending in Canada, and Hong Kong. * Arecent DEA finding that CB…

Slide 12

Physical Challenges to Ocular Drug Delivery Blood-Retinal Barrier Blood-Aqueous Ciliary Body Barrier Iris Aqueous Humor Optic Nerve W, ' / Comca - 1§ —.! Sclera (—- / Choroid —3 Retina R x Conjunctiva * Blood-retinal barrier * Most effective route into the eye for * Blood-aqueous humor barrier lipophilic cannabinoids is to re-engineer the e Corneal-scleral barrier molecule so it effectively traverses the cornea 12

Slide text above is read directly from the Nemus Bioscience deck PDF embedded on this page.